

**Next Steps and Closing Remarks**  
*Hunt Willard, Ph.D.*

---

DR. WILLARD: Thank you to Emily and the task force. That was a terrific, albeit exhausting, day. My thanks to the speakers as well. I think we never fail to learn something, and today we actually learned an enormous amount, and I thank you all for that.

It falls on me simply to announce our next meeting is October 19th and 20th, and at least currently is scheduled to be held here again according to my notes. The meeting dates for next year are in your table folders, for those who like to plan your long-range calendars.

I think all of us want to both recognize and thank and say goodbye to Barbara and Joan, this being your last meeting. Ed has already totally forgotten he was ever on this committee, I'm sure.

(Laughter.)

DR. WILLARD: His 12 hours have passed.

But you've been terrific participants, and we will miss you and wish you well in your retirement.

Any other business?

DR. LEONARD: Sarah, are the meeting dates set for going out?

MS. CARR: For 2006? They were supposed to be, but we're having to work on them. We haven't found sites for those meetings yet, so we're holding off on setting them in stone yet. But we hope to do it very soon because we know your calendars will fill up soon.

DR. LEONARD: Could you send out at least tentative dates that we could hold?

MS. CARR: Could we do that? Yes, we can certainly do that.

DR. WILLARD: March, June and October.

(Laughter.)

MS. CARR: Don't put anything on those months.

DR. WILLARD: Suzanne?

DR. FEETHAM: A theme that has been going through the whole work of SACGHS, and certainly these last two days, is access. I'm bringing it up separately from the pharmacogenomics because it really is underlying everything we've been talking about. In talking with Tim, I know a fair amount of studies have been funded through the ELSI regarding access. What we don't know is if they have solid evidence to report about that. But that's something I'd like us to think about for a future meeting and have our colleagues do the homework to know whether they're at a point where they'd want to be presenting that. But I think that's just critically important, underlying all of the work we're doing, and if the science is moving along in that area, it would behoove us to know what the state of the science is.

SACGHS Meeting Transcript  
June 15-16, 2005

DR. WILLARD: Thank you for that. Access, of course, is one of those overarching issues we identified early on, and we do need to keep coming back to it. So I appreciate that.

Agnes?

MS. MASNY: Not that I want any more work, but just the beautiful chart that we put up regarding the timeline of all the priority areas, is there anything else that we have to address besides the pharmacogenomics for the next meeting?

DR. WILLARD: Large population studies is the other major one.

Well, with that, and seeing no other red lights, thank you to everyone, both on the committee and in the audience, and those who are still hanging in at home. With that, this meeting will be adjourned. Thank you all.

(Whereupon, at 4:21 p.m., the meeting was adjourned.)